Assessment of reporting quality of meta-analyses of randomized controlled trials in neovascular age-related macular degeneration published from April 2014 to May 2018 using prisma statement.

Abstract

To evaluate the reporting quality of meta-analysis on neovascular age-related macular degeneration treatment and safety profile based on PRISMA statement. Electronic search performed in August 2018 to retrieve meta-analyses published from April 2014 to May 2018. PRISMA evaluation was determined by total scores of individual meta-analyses and items scores. Statistical analysis of parameters affecting the reporting evaluation included subgroup multivariate analysis and regression analysis. Twelve meta-analyses were finally included, three being Cochrane systematic reviews. Mean PRISMA score is 23.2/27 (86.1%). Eleven PRISMA ITEMS had significantly higher %score in 12 meta-analyses than in nine non-Cochrane meta-analyses measurements. Positive strong correlation identified between PRISMA %score and journal impact factor (JIF). Multivariate analysis between high-scored and low-scored meta-analyses established difference in means of several parameters (JIF, Publication Year). The evaluation of overall reporting quality was favorable. As expected, the key role of several characteristics of meta-analysis affects this quality. Under-reporting of specific items (protocol, search strategy and assessment of risk of bias) indicates the urgency for PRISMA compliance.